US Pharma MarketingTurning AI skeptics into AI advocates through high-integrity data
With 89% of AI pilots failing to scale, biopharmas can move from data skepticism to advocacy by building a trusted, globally harmonized foundation.
With 89% of AI pilots failing to scale, biopharmas can move from data skepticism to advocacy by building a trusted, globally harmonized foundation.
Source: Pharmaceutical Technology